MCID: BRS099
MIFTS: 57

Breast Ductal Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Breast Ductal Carcinoma

MalaCards integrated aliases for Breast Ductal Carcinoma:

Name: Breast Ductal Carcinoma 12 15
Ductal Breast Carcinoma 56 6 74
Mammary Ductal Carcinoma 74
Carcinoma, Ductal 45
Ductal Carcinoma 74
Duct Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3007
MeSH 45 D044584
SNOMED-CT 69 82711006

Summaries for Breast Ductal Carcinoma

Disease Ontology : 12 A breast carcinoma that derives from the lining of milk ducts.

MalaCards based summary : Breast Ductal Carcinoma, also known as ductal breast carcinoma, is related to bile duct cancer and comedo carcinoma. An important gene associated with Breast Ductal Carcinoma is RAD54L (RAD54 Like), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Epirubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and liver, and related phenotypes are Decreased cell migration and Decreased viability in esophageal squamous lineage

Related Diseases for Breast Ductal Carcinoma

Diseases related to Breast Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 303, show less)
# Related Disease Score Top Affiliating Genes
1 bile duct cancer 32.9 CCND1 EGFR MET TP53
2 comedo carcinoma 32.8 ERBB2 ESR1
3 intrahepatic cholangiocarcinoma 32.7 CDH1 CTNNB1 EGFR TP53
4 renal cell carcinoma, nonpapillary 32.6 CDH1 EGFR KRT8 MET
5 breast cystic hypersecretory carcinoma 32.4 CDH1 ERBB2
6 cholangiocarcinoma 31.3 CCND1 CDH1 CTNNB1 EGFR ERBB2 KRT8
7 pleomorphic adenoma carcinoma 31.2 ERBB2 TP53
8 in situ carcinoma 31.0 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
9 pleomorphic adenoma 30.7 AR ERBB2 TP53
10 renal cell carcinoma, papillary, 1 30.4 ERBB2 MET TP53
11 adenocarcinoma 30.4 CCND1 CDH1 CTNNB1 EGFR ERBB2 TP53
12 cystadenocarcinoma 30.1 ERBB2 PGR TP53
13 transitional cell carcinoma 30.0 CDH1 EGFR ERBB2 KRT8 TP53
14 ductal carcinoma in situ 29.9 AR BRCA1 CCND1 CDH1 EGFR ERBB2
15 papillary adenocarcinoma 29.9 CDH1 ERBB2 PGR TP53
16 adenoid cystic carcinoma 29.8 CCND1 CDH1 CTNNB1 ERBB2 PGR TP53
17 breast carcinoma in situ 29.8 BRCA1 EGFR ERBB2 ESR1 MET PGR
18 papillary carcinoma 29.8 CDH1 ERBB2 MET PGR
19 bladder urothelial carcinoma 29.6 CCND1 CDH1 CTNNB1 ERBB2 TP53 VEGFC
20 thyroid cancer 29.6 CCND1 CDH1 CTNNB1 EGFR MET TP53
21 breast fibroadenoma 29.6 ERBB2 ESR1 KRT8 NME1 PGR
22 sweat gland cancer 29.5 ERBB2 ESR1 KRT8 PGR TP53
23 squamous cell carcinoma 29.5 CCND1 CDH1 CTNNB1 EGFR ERBB2 NME1
24 breast disease 29.4 BRCA1 CTSD ERBB2 ESR1 PGR TFF1
25 mammary paget's disease 29.4 EGFR ERBB2 ESR1 KRT8 PGR
26 breast cancer 26.1 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
27 collecting duct carcinoma 12.6
28 adenosquamous bile duct carcinoma 12.3
29 bile duct carcinoma in situ 12.2
30 nipple duct carcinoma 12.1
31 squamous cell bile duct carcinoma 12.1
32 distal biliary tract carcinoma 11.4
33 cribriform carcinoma 11.2
34 klatskin's tumor 11.1
35 extrahepatic bile duct small cell adenocarcinoma 11.1
36 renal cell carcinoma, xp11-associated 11.0
37 extrahepatic bile duct adenocarcinoma 11.0
38 bile duct adenocarcinoma 11.0
39 cerebral convexity meningioma 10.6 CDH1 TP53
40 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
41 adult hepatocellular carcinoma 10.5 CTNNB1 TP53
42 breast papillomatosis 10.5 CCND1 ERBB2
43 breast malignant phyllodes tumor 10.5 PGR TP53
44 brain ependymoma 10.5 EGFR TP53
45 recurrent respiratory papillomatosis 10.5 EGFR TP53
46 intracystic papillary adenoma 10.5 ERBB2 PGR
47 breast metaplastic carcinoma 10.5 ERBB2 PGR
48 vulvar benign neoplasm 10.5 ESR1 PGR
49 trigonitis 10.5 ESR1 PGR
50 bartholin's gland benign neoplasm 10.5 ESR1 PGR
51 vulvar leiomyoma 10.5 ESR1 PGR
52 predominantly cortical thymoma 10.5 ESR1 PGR
53 calcifying epithelial odontogenic tumor 10.4 KRT8 TP53
54 ureteral obstruction 10.4 CTNNB1 TP53 VEGFC
55 tuberculous salpingitis 10.4 BRCA1 ERBB2
56 respiratory system disease 10.4 CDH1 EGFR TP53
57 serous cystadenocarcinoma 10.4 ERBB2 PGR TP53
58 ovarian serous cystadenocarcinoma 10.4 ERBB2 PGR TP53
59 adenomyosis 10.4 CDH1 ESR1 PGR
60 lymphangioleiomyomatosis 10.4 ESR1 PGR VEGFC
61 nervous system cancer 10.4 CCND1 EGFR TP53
62 non-proliferative fibrocystic change of the breast 10.4 CCND1 ERBB2 TP53
63 nosophobia 10.3 BRCA1 PGR
64 cancerophobia 10.3 BRCA1 PGR
65 differentiated thyroid carcinoma 10.3 EGFR MET TP53
66 endometrium carcinoma in situ 10.3 PGR TP53
67 bile duct cystadenocarcinoma 10.3
68 glassy cell carcinoma of the cervix 10.3 ERBB2 ESR1 PGR
69 tonsil cancer 10.3 CDH1 ERBB2 TP53
70 vestibular gland benign neoplasm 10.3 ESR1 PGR
71 scirrhous adenocarcinoma 10.3 ERBB2 PGR
72 uterine body mixed cancer 10.3 ERBB2 PGR TP53
73 breast squamous cell carcinoma 10.3 EGFR ERBB2 TP53
74 postmenopausal atrophic vaginitis 10.3 AR ESR1
75 progesterone-receptor positive breast cancer 10.3 ERBB2 ESR1 PGR
76 cervical carcinosarcoma 10.3 ESR1 PGR TP53
77 melanoma, uveal 10.3 KRT8 MET VEGFC
78 bartholin's gland adenoma 10.3 ESR1 PGR
79 breast apocrine carcinoma 10.3 ERBB2 PGR
80 tongue disease 10.3 CDH1 CTNNB1 TP53 VEGFC
81 adenosarcoma 10.3 ESR1 PGR TP53
82 adenoma 10.3
83 endometrial clear cell adenocarcinoma 10.3 CTSD ESR1
84 mixed cell type cancer 10.3 ERBB2 PGR TP53
85 breast intraductal proliferative lesion 10.3 EGFR ERBB2
86 bladder disease 10.3 CCND1 CDH1 ERBB2 TP53
87 intestinal benign neoplasm 10.3 CCND1 CTNNB1 TP53
88 nasopharyngeal disease 10.3 CCND1 CDH1 CTNNB1 TP53
89 cervix disease 10.2 CCND1 CDH1 CTNNB1 TP53
90 progesterone-receptor negative breast cancer 10.2 EGFR ERBB2 PGR
91 esophageal basaloid squamous cell carcinoma 10.2 CTNNB1 EGFR TP53
92 li-fraumeni syndrome 10.2 BRCA1 EGFR TP53
93 tongue squamous cell carcinoma 10.2 CDH1 CTNNB1 TP53 VEGFC
94 uterine corpus serous adenocarcinoma 10.2 BRCA1 ERBB2 TP53
95 carcinosarcoma 10.2 CTNNB1 ERBB2 PGR TP53
96 tubular adenocarcinoma 10.2 CDH1 ERBB2 ESR1 PGR
97 oropharynx cancer 10.2 CCND1 CDH1 EGFR TP53
98 female reproductive endometrioid cancer 10.2 CTNNB1 ESR1 PGR TP53
99 penile cancer 10.2 CCND1 EGFR TP53
100 cervical adenocarcinoma 10.2 ERBB2 ESR1 PGR TP53
101 chordoma 10.2 CDH1 EGFR MET
102 breast osteosarcoma 10.2 ERBB2 KRT8
103 familial adenomatous polyposis 10.2 CCND1 CDH1 CTNNB1 TP53
104 oral cancer 10.2 CCND1 CDH1 EGFR TP53
105 esophageal disease 10.2 CCND1 EGFR ERBB2 TP53
106 colorectal adenocarcinoma 10.2 CDH1 CTNNB1 EGFR TP53
107 oral cavity cancer 10.2 CDH1 EGFR ERBB2 TP53
108 meningioma, familial 10.2 CDH1 ESR1 PGR TP53
109 papillary serous adenocarcinoma 10.2 BRCA1 PGR TP53
110 endometrial stromal sarcoma 10.2 CCND1 ESR1 PGR TP53
111 pleomorphic carcinoma 10.2 EGFR KRT8 TP53
112 tongue cancer 10.2 CCND1 CDH1 CTNNB1 TP53 VEGFC
113 cervical clear cell adenocarcinoma 10.2 ESR1 KRT8 PGR
114 mutagen sensitivity 10.2 BRCA1 CCND1 TP53
115 vulvar syringoma 10.2 ESR1 PGR
116 breast scirrhous carcinoma 10.1 EGFR ERBB2 ESR1 PGR
117 leiomyosarcoma 10.1
118 basaloid squamous cell carcinoma 10.1 EGFR KRT8 TP53
119 breast secretory carcinoma 10.1 ERBB2 KRT8 PGR
120 luminal breast carcinoma 10.1 EGFR ERBB2 ESR1 PGR
121 ovarian cancer 1 10.1 BRCA1 CDH1 ERBB2 TP53
122 cervical squamous cell carcinoma 10.1 CDH1 CTNNB1 KRT8 TP53
123 ulcerative colitis 10.1
124 colitis 10.1
125 atypical teratoid rhabdoid tumor 10.1 CCND1 CTNNB1 TP53
126 malignant syringoma 10.1
127 cholangitis 10.1
128 infiltrative basal cell carcinoma 10.1 AR CDH1 FAP
129 medulloblastoma 10.1 CCND1 CTNNB1 EGFR ERBB2 TP53
130 bilateral breast cancer 10.1 BRCA1 ERBB2 PGR
131 sarcoma, synovial 10.1 CDH1 CTNNB1 KRT8 MET
132 pharynx cancer 10.1 CCND1 CDH1 CTNNB1 EGFR TP53
133 glycogen-rich clear cell breast carcinoma 10.1 BRCA1 ESR1 PGR TP53
134 intestinal disease 10.1 CCND1 CDH1 CTNNB1 EGFR TP53
135 spinal chordoma 10.1 EGFR KRT8 MET
136 barrett esophagus 10.1 CCND1 ERBB2 TFF1 TP53
137 male reproductive system disease 10.1 AR CCND1 CDH1 TP53
138 breast medullary carcinoma 10.1 BRCA1 ERBB2 ESR1 PGR
139 hypoxia 10.1
140 peritoneal benign neoplasm 10.1 AR ESR1 PGR
141 gender identity disorder 10.1 AR ESR1 PGR
142 inflammatory breast carcinoma 10.0 CDH1 EGFR ERBB2 ESR1 PGR
143 diffuse peritoneal leiomyomatosis 10.0 AR ESR1 PGR
144 glioblastoma 10.0 CCND1 EGFR ERBB2 MET TP53
145 glioblastoma multiforme 10.0 CCND1 EGFR ERBB2 MET TP53
146 lobular neoplasia 10.0 BRCA1 CDH1 CTNNB1 ERBB2 ESR1
147 breast adenocarcinoma 10.0 CTSD EGFR ERBB2 ESR1 TP53
148 large intestine adenocarcinoma 10.0 CDH1 CTNNB1 PIP
149 bile duct cysts 10.0
150 sclerosing cholangitis 10.0
151 giant cell tumor 10.0
152 eyelid carcinoma 10.0
153 suppression of tumorigenicity 12 10.0 AR CDH1 CTNNB1 TP53
154 lung leiomyoma 10.0 ESR1 PGR
155 apocrine adenocarcinoma 10.0 AR ERBB2 ESR1 PGR
156 uterine corpus cancer 10.0 BRCA1 ERBB2 ESR1 PGR TP53
157 breast adenoid cystic carcinoma 10.0 AR ERBB2 ESR1 PGR
158 fallopian tube carcinoma 10.0 BRCA1 ERBB2 ESR1 PGR TP53
159 ovarian disease 10.0 BRCA1 ESR1 PGR TP53
160 gastrointestinal system disease 10.0 CCND1 CDH1 CTNNB1 EGFR ERBB2 TP53
161 synchronous bilateral breast carcinoma 10.0 BRCA1 CCND1 ESR1 PGR TP53
162 sporadic breast cancer 10.0 BRCA1 ERBB2 ESR1 PGR TP53
163 gastric signet ring cell adenocarcinoma 9.9 CDH1 PGR PIP
164 uterine carcinosarcoma 9.9 CDH1 CTNNB1 EGFR ERBB2 PGR TP53
165 laryngeal disease 9.9 CCND1 CDH1 EGFR NME1 TP53
166 obstructive jaundice 9.9
167 kidney disease 9.9
168 estrogen-receptor positive breast cancer 9.9 CCND1 EGFR ERBB2 ESR1 PGR TP53
169 laryngeal squamous cell carcinoma 9.9 CCND1 CDH1 EGFR NME1 TP53
170 bladder cancer 9.9 CCND1 CDH1 EGFR ERBB2 TP53 ZFAS1
171 gallbladder cancer 9.9 CDH1 EGFR ERBB2 NME1 TP53
172 lynch syndrome 9.9 BRCA1 CCND1 CTNNB1 EGFR TP53
173 primary peritoneal carcinoma 9.9 BRCA1 EGFR ERBB2 PGR TP53
174 male reproductive organ cancer 9.9 AR CCND1 CDH1 CTNNB1 TP53
175 leiomyoma, uterine 9.9
176 lipomatosis, multiple 9.9
177 thyroid cancer, nonmedullary, 1 9.9
178 lymphoma, hodgkin, classic 9.9
179 pituitary adenoma, prolactin-secreting 9.9
180 lymphoma, non-hodgkin, familial 9.9
181 body mass index quantitative trait locus 1 9.9
182 infantile liver failure syndrome 1 9.9
183 acute liver failure 9.9
184 leukemia 9.9
185 lymphoma 9.9
186 pleomorphic lipoma 9.9
187 mastitis 9.9
188 leiomyoma 9.9
189 pneumothorax 9.9
190 linitis plastica 9.9
191 breast lymphoma 9.9
192 prostatic hypertrophy 9.9 AR EGFR ESR1 PGR
193 cervical intraepithelial neoplasia 9.9 KRT8 NME1 VEGFC
194 malignant ovarian surface epithelial-stromal neoplasm 9.9 BRCA1 CDH1 ERBB2 ESR1 PGR TP53
195 ovary epithelial cancer 9.9 BRCA1 CDH1 ERBB2 ESR1 PGR TP53
196 uterine anomalies 9.9 CCND1 CDH1 CTNNB1 ERBB2 ESR1 PGR
197 gynecomastia 9.9 AR ESR1 PGR
198 adenosquamous carcinoma 9.8 AR EGFR KRT8 TP53
199 cholangitis, primary sclerosing 9.8
200 hepatitis 9.8
201 thrombosis 9.8
202 neuroma 9.8
203 mucoepidermoid carcinoma 9.8
204 myoepithelial carcinoma 9.8
205 epithelial-myoepithelial carcinoma 9.8
206 chromophil renal cell carcinoma 9.8
207 respiratory system cancer 9.8 CCND1 CDH1 CTNNB1 EGFR ERBB2 MET
208 gastrointestinal system cancer 9.8 CCND1 CDH1 CTNNB1 EGFR ERBB2 MET
209 endometrial squamous cell carcinoma 9.8 AR CCND1 ESR1 MET PGR
210 esophageal cancer 9.8 CCND1 CDH1 CTNNB1 EGFR ERBB2 TP53
211 larynx cancer 9.8 CCND1 CTSD EGFR NME1 TP53
212 hepatocellular carcinoma 9.8 CCND1 CDH1 CTNNB1 EGFR MET TP53
213 breast neuroendocrine neoplasm 9.8 ERBB2 PIP
214 glioma 9.8 CCND1 EGFR ERBB2 FAP MET TP53
215 bartholin's duct cyst 9.8 AR PIP TP53
216 nasopharyngeal carcinoma 9.8 CCND1 CDH1 EGFR NME1 TP53 VEGFC
217 colonic disease 9.8 CCND1 CDH1 CTNNB1 CTSD EGFR ESR1
218 gonadal disease 9.8 AR BRCA1 ERBB2 ESR1 TP53
219 acinar cell carcinoma 9.8
220 breast benign neoplasm 9.8 ERBB2 ESR1 PGR PIP TP53
221 thoracic benign neoplasm 9.8 ERBB2 ESR1 PGR PIP TP53
222 paget disease, extramammary 9.7 AR ERBB2 PIP
223 cervical cancer 9.7 CCND1 CDH1 CTNNB1 ERBB2 NME1 TP53
224 wilms tumor 1 9.7 AR CTNNB1 ERBB2 ESR1 PGR TP53
225 endometrial adenocarcinoma 9.7 CTNNB1 CTSD EGFR ERBB2 ESR1 PGR
226 squamous cell carcinoma, head and neck 9.7 CCND1 CDH1 CTNNB1 EGFR ERBB2 MET
227 estrogen-receptor negative breast cancer 9.7 AR BRCA1 ERBB2 ESR1 PGR
228 microglandular adenosis 9.7 EGFR ERBB2 PGR PIP TP53
229 autoimmune disease 9.7
230 retinoblastoma 9.7
231 varicose veins 9.7
232 chondrosarcoma 9.7
233 donohue syndrome 9.7
234 oncocytoma 9.7
235 renal dysplasia, cystic 9.7
236 alpha-1-antitrypsin deficiency 9.7
237 meconium ileus 9.7
238 pontine tegmental cap dysplasia 9.7
239 chromophobe renal cell carcinoma 9.7
240 end stage renal failure 9.7
241 hepatitis b 9.7
242 liver disease 9.7
243 nephrolithiasis 9.7
244 pancreatic ductal adenocarcinoma 9.7
245 inflammatory myofibroblastic tumor 9.7
246 sialadenitis 9.7
247 cholecystolithiasis 9.7
248 portal vein thrombosis 9.7
249 choledocholithiasis 9.7
250 telangiectasis 9.7
251 cholestasis 9.7
252 extrahepatic cholestasis 9.7
253 benign breast phyllodes tumor 9.7
254 syringoma 9.7
255 kidney cancer 9.7
256 cystadenoma 9.7
257 mucinous adenocarcinoma 9.7
258 appendix adenocarcinoma 9.7
259 pleural empyema 9.7
260 spindle cell carcinoma 9.7
261 cutaneous fibrous histiocytoma 9.7
262 clear cell renal cell carcinoma 9.7
263 sarcomatoid renal cell carcinoma 9.7
264 pancreatitis 9.7
265 keratinizing squamous cell carcinoma 9.7
266 adenoid squamous cell carcinoma 9.7
267 malignant acrospiroma 9.7
268 paraplegia 9.7
269 situs inversus 9.7
270 hard palate cancer 9.7
271 urethral diverticulum 9.7
272 polycystic kidney disease 9.7
273 congenital hepatic fibrosis 9.7
274 desmoplastic infantile ganglioglioma 9.7
275 left-sided gallbladder 9.7
276 polymorphous low-grade adenocarcinoma 9.7
277 warthin tumor 9.7
278 multicystic dysplastic kidney 9.7
279 lymphomatous meningitis 9.7
280 argyria 9.7
281 papillary hidradenoma 9.7 AR PGR PIP
282 bartholin's gland disease 9.6 AR PGR PIP TP53
283 hidradenocarcinoma 9.6 CCND1 EGFR ERBB2 ESR1 PIP TP53
284 stomach disease 9.6 CCND1 CDH1 CTNNB1 EGFR ERBB2 MET
285 female breast cancer 9.6 AR BRCA1 ERBB2 ESR1 PGR TP53
286 lipid-rich carcinoma 9.6 CDH1 EGFR ERBB2 ESR1 PGR PIP
287 pancreas adenocarcinoma 9.6 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
288 pancreatic cancer 9.5 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
289 oncocytic breast carcinoma 9.4 AR EGFR ESR1 PGR PIP
290 female reproductive system disease 9.4 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
291 large intestine cancer 9.4 CCND1 CDH1 CTNNB1 EGFR ERBB2 MET
292 lung cancer 9.4 CCND1 CDH1 EGFR ERBB2 MET NME1
293 adamantinoma of long bones 9.3 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
294 lung cancer susceptibility 3 9.2 CCND1 CDH1 CTNNB1 EGFR ERBB2 MET
295 endocrine gland cancer 9.2 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
296 pre-malignant neoplasm 9.1 BRCA1 CCND1 CDH1 EGFR ERBB2 ESR1
297 reproductive system disease 9.1 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
298 gastric cancer 9.0 CCND1 CDH1 CTNNB1 EGFR ERBB2 MET
299 ovarian cancer 8.9 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
300 endometrial cancer 8.9 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
301 gastric adenocarcinoma 8.8 CCND1 CDH1 CTNNB1 CTSD EGFR ERBB2
302 colorectal cancer 8.8 BRCA1 CCND1 CDH1 CTNNB1 CTSD EGFR
303 prostate cancer 8.7 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR

Graphical network of the top 20 diseases related to Breast Ductal Carcinoma:



Diseases related to Breast Ductal Carcinoma

Symptoms & Phenotypes for Breast Ductal Carcinoma

GenomeRNAi Phenotypes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

27 (showing 4, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.65 CTNNB1 CTSD EGFR MET VEGFC
2 Decreased viability in esophageal squamous lineage GR00235-A 9.65 BRCA1 CCND1 CDH1 CTNNB1 ERBB2 ESR1
3 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 CTNNB1 CTSD EGFR ERBB2 VEGFC
4 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 CTNNB1 EGFR PGR PIP TP53

MGI Mouse Phenotypes related to Breast Ductal Carcinoma:

47 (showing 24, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
2 cellular MP:0005384 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
3 homeostasis/metabolism MP:0005376 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
4 digestive/alimentary MP:0005381 10.44 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
5 endocrine/exocrine gland MP:0005379 10.43 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
6 growth/size/body region MP:0005378 10.42 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
7 immune system MP:0005387 10.42 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
8 mortality/aging MP:0010768 10.4 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
9 hematopoietic system MP:0005397 10.35 AR BRCA1 CCND1 CTNNB1 CTSD EGFR
10 embryo MP:0005380 10.33 AR BRCA1 CDH1 CTNNB1 EGFR ERBB2
11 integument MP:0010771 10.31 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
12 neoplasm MP:0002006 10.27 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
13 limbs/digits/tail MP:0005371 10.18 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
14 nervous system MP:0003631 10.17 AR BRCA1 CCND1 CTNNB1 CTSD EGFR
15 craniofacial MP:0005382 10.15 AR CCND1 CTNNB1 EGFR ERBB2 MET
16 normal MP:0002873 10.15 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
17 muscle MP:0005369 10.13 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
18 liver/biliary system MP:0005370 10.11 AR CTNNB1 EGFR ESR1 KRT8 MET
19 no phenotypic analysis MP:0003012 9.95 CDH1 CTNNB1 EGFR ESR1 MET PGR
20 reproductive system MP:0005389 9.93 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
21 renal/urinary system MP:0005367 9.8 AR BRCA1 CTNNB1 EGFR ESR1 MET
22 pigmentation MP:0001186 9.72 AR BRCA1 CTNNB1 EGFR TP53
23 respiratory system MP:0005388 9.56 BRCA1 CCND1 CTNNB1 EGFR ERBB2 ESR1
24 skeleton MP:0005390 9.28 AR BRCA1 CCND1 CTNNB1 EGFR ERBB2

Drugs & Therapeutics for Breast Ductal Carcinoma

Drugs for Breast Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 192, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Pertuzumab Approved Phase 3,Phase 2 380610-27-5, 145040-37-5 2540
5
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
6
Tamoxifen Approved Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
7
Sodium Citrate Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
8
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
9
Fulvestrant Approved, Investigational Phase 3,Phase 2,Not Applicable 129453-61-8 17756771 104741
10
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
11
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
12
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
13
Carboplatin Approved Phase 2, Phase 3,Phase 3 41575-94-4 10339178 38904 498142
14
Trastuzumab Approved, Investigational Phase 2, Phase 3,Phase 3 180288-69-1 9903
15
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
16
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
17
Toremifene Approved, Investigational Phase 3 89778-26-7 3005573
18
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
19
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
20
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
21
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
22
Metformin Approved Phase 3 657-24-9 14219 4091
23
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
24
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 657181 3911
25
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
26
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
27
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
28
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
30
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
31
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
32
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Not Applicable 231277-92-2, 388082-78-8 208908 9941095
33 Atamestane Investigational Phase 3 96301-34-7
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
36 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
39 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
40 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
41 Citrate Phase 3,Phase 2,Phase 1,Not Applicable
42 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
43 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
44 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1,Not Applicable
45 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
46 Aromatase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
47 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
48 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
49 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
50 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
51 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
52 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
53 Chelating Agents Phase 3,Phase 2,Not Applicable
54 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
55 Alkylating Agents Phase 3,Phase 2,Phase 1
56 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
57 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
58 Immunologic Factors Phase 3,Phase 2,Phase 1
59 Gastrointestinal Agents Phase 3
60 Angiogenesis Modulating Agents Phase 2, Phase 3
61 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
62 Protein Kinase Inhibitors Phase 2, Phase 3,Not Applicable
63 Angiogenesis Inhibitors Phase 2, Phase 3
64 Ferric Compounds Phase 3
65 Hematinics Phase 3
66 Contraceptive Agents, Male Phase 3
67 Estrogens, Conjugated (USP) Phase 3,Phase 2
68
Medroxyprogesterone Phase 3 520-85-4 10631
69 Contraceptive Agents Phase 3
70 Contraceptives, Oral Phase 3
71 Anti-Allergic Agents Phase 3
72 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
73 Dermatologic Agents Phase 3,Phase 1
74 Mitogens Phase 3,Phase 2,Early Phase 1
75 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
76 Anti-Infective Agents Phase 3,Phase 1
77 Neurotransmitter Agents Phase 3,Not Applicable
78 Anticoagulants Phase 3,Phase 2,Not Applicable
79 Calcium, Dietary Phase 3,Phase 2,Phase 1,Not Applicable
80 Antimetabolites Phase 3,Phase 2,Phase 1
81 Hypoglycemic Agents Phase 3
82 Antibodies, Monoclonal Phase 3,Phase 2
83 Immunoglobulins Phase 3,Phase 2
84 Antibodies Phase 3,Phase 2
85 Antimetabolites, Antineoplastic Phase 3,Phase 1
86 Autonomic Agents Phase 3
87 Mandelic Acids Phase 3
88 Muscarinic Antagonists Phase 3
89 Anti-Infective Agents, Urinary Phase 3
90 Cholinergic Antagonists Phase 3
91 Renal Agents Phase 3
92 Cholinergic Agents Phase 3
93 Parasympatholytics Phase 3
94 Progestins Phase 3
95
Melphalan Approved Phase 2 148-82-3 460612 4053
96
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
97
Vorinostat Approved, Investigational Phase 2,Phase 1 149647-78-9 5311
98
Simvastatin Approved Phase 2 79902-63-9 54454
99
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
100
Polyestradiol phosphate Approved Phase 2 28014-46-2
101
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
102
Bazedoxifene Approved, Investigational Phase 2 198481-32-2
103
Talimogene laherparepvec Approved, Experimental, Investigational Phase 1, Phase 2 1187560-31-1
104
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
105
Iodine Approved, Investigational Phase 2 7553-56-2 807
106
Denosumab Approved Phase 2 615258-40-7
107
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
108
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
109
St. John's Wort Approved, Investigational, Nutraceutical Phase 2 84082-80-4
110
Afimoxifene Investigational Phase 2 68392-35-8
111
Sulforaphane Investigational Phase 2 4478-93-7, 142825-10-3 5350
112 Omega 3 Fatty Acid Phase 2,Not Applicable
113 Hydroxytamoxifen Phase 2
114 Protective Agents Phase 2
115 Sulforafan Phase 2
116 Histone Deacetylase Inhibitors Phase 2,Phase 1
117 Hypolipidemic Agents Phase 2,Phase 1
118 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2,Phase 1
119 Lipid Regulating Agents Phase 2,Phase 1
120 Anticholesteremic Agents Phase 2,Phase 1
121 Imatinib Mesylate Phase 2 220127-57-1 123596
122 Estradiol 3-benzoate Phase 2
123 Estradiol 17 beta-cypionate Phase 2
124 Soy Bean Phase 2,Not Applicable
125 taxane Phase 2,Not Applicable
126 Vaccines Phase 2,Phase 1
127 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1,Not Applicable
128 Analgesics, Non-Narcotic Phase 2,Phase 1,Not Applicable
129 Analgesics Phase 2,Phase 1,Not Applicable
130 Cyclooxygenase Inhibitors Phase 2,Phase 1
131 Triamcinolone hexacetonide Phase 2
132 Triamcinolone diacetate Phase 2
133 triamcinolone acetonide Phase 2
134 Follicle Stimulating Hormone Phase 2,Not Applicable
135 Cyclooxygenase 2 Inhibitors Phase 2
136
Aldesleukin Approved Phase 1 110942-02-4, 85898-30-2
137
Atorvastatin Approved Phase 1 134523-00-5 60823
138
Sulindac Approved, Investigational Phase 1 38194-50-2 1548887 5352
139
Ritonavir Approved, Investigational Phase 1 155213-67-5 392622
140
Methotrexate Approved Phase 1 1959-05-2, 59-05-2 126941
141
leucovorin Approved Phase 1 58-05-9 143 6006
142
Bexarotene Approved, Investigational Phase 1 153559-49-0 82146
143
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1,Not Applicable 1406-16-2
144
Vitamin D3 Approved, Nutraceutical Phase 1,Not Applicable 67-97-0 5280795 6221
145
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
146
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
147 Antiviral Agents Phase 1
148 Muromonab-CD3 Phase 1
149 Anti-HIV Agents Phase 1
150 Anti-Retroviral Agents Phase 1
151
protease inhibitors Phase 1
152 Cytochrome P-450 Enzyme Inhibitors Phase 1
153 Anesthetics Phase 1,Not Applicable
154 HIV Protease Inhibitors Phase 1
155 Cytochrome P-450 CYP3A Inhibitors Phase 1
156 Vitamins Phase 1,Not Applicable
157 Nutrients Phase 1,Not Applicable
158 Trace Elements Phase 1,Not Applicable
159 Micronutrients Phase 1,Not Applicable
160 Calciferol Phase 1,Not Applicable
161 Vitamin B9 Phase 1
162 Folate Phase 1
163 Vitamin B Complex Phase 1
164 Folic Acid Antagonists Phase 1
165 Nucleic Acid Synthesis Inhibitors Phase 1
166 Ergocalciferols Phase 1
167 Vitamin D2 Phase 1
168
tannic acid Approved Not Applicable 1401-55-4
169
Benzocaine Approved, Investigational Not Applicable 1994-09-7, 94-09-7 2337
170
Ethanol Approved 64-17-5 702